Identifying the perfect first-line prevention medication therapy will have a transformational effect on the field, provides Dr. Powers, who also directs the Office for Clinical and Translational Research at Cincinnati Children’s, a combined group that will provide critical support to this effort. The results of the trial changes current scientific practice by ensuring that decisions on early, effective treatment for an incredible number of adolescents and children with migraine is now able to depend on sound evidence. .. Cincinnati Children’s to carry out first pediatric migraine medication clinical trial Cincinnati Children’s Hospital Medical Center has received a $12 million grant from the National Institutes of Wellness to conduct the first clinical trial to determine the medication of preference for preventing migraines in children and teens.Amgen announces top-line outcomes from motesanib Phase 3 trial against NSCLC Amgen , Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Firm Small today announced top-line outcomes from the MONET1 pivotal Stage 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung tumor . The trial did not meet its primary objective of demonstrating an improvement in overall survival . We are disappointed with the results from this trial, but anticipate further evaluation of the data which might ultimately help inform future research in this region, said Roger M.